Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells

Biological Chemistry

Volumn 391, Issue 4, 2010, Pages 461-466

  Whitbread, Astrid K ^a,b   Veveris Lowe, Tara L ^a   Dong, Ying ^a   Tan, Olivia L ^a   Gardiner, Robert ^c   Samaratunga, Hema M ^d   Nicol, David L ^e,f   Clements, Judith A ^a,f  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b Wesley Research Institute   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d AQUESTA Specialised Uropathology   (Australia)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f Translational Research Institute   (Australia)

Author keywords

Alternative splicing; Biomarker; Kallikrein related peptidase; Prostate specific antigen (PSA)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SEQUENCE; CANCER CELL CULTURE; CELL PROLIFERATION; CONFERENCE PAPER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN SECRETION; PSA GENE; RNA SPLICING;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEIN TRANSPORT;

PAN; PRIMATES;

EID: 77951493223     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2010.043     Document Type: Conference Paper

References (22)

1. Borgono, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
2. Clements, J.A., Willemsen, N.M., Myers, S.A., and Dong, Y. (2004). The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 41, 265-312.
3. David, A., Mabjeesh, N., Azar, I., Biton, S., Engel, S., Bernstein, J., Romano, J., Avidor, Y., Waks, T., Eshhar, Z., et al. (2002). Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J. Biol. Chem. 277, 18084-18090.
4. Dong, Y., Bui, L.T., Odorico, D.M., Tan, O.L., Myers, S.A., Samaratunga, H., Gardiner, R.A., and Clements, J.A. (2005). Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. Endocr. Relat. Cancer 12, 875-889.
5. Dorus, S., Evans, P.D., Wyckoff, G.J., Choi, S.S., and Lahn, B.T. (2004). Rate of molecular evolution of the seminal protein gene SEMG2 correlates with levels of female promiscuity. Nat. Genet. 36, 1326-1369.
6. Fortier, A.H., Holaday, J.W., Liang, H., Dey, C., Grella, D.K., Holland-Linn, J., Vu, H., Plum, S.M., and Nelson, B.J. (2003). Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 56, 212-219.
7. Gao, J., Collard, R.L., Bui, L., Herington, A.C., Nicol, D.L., and Clements, J.A. (2007). Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate 67, 348-360.
8. Heuze-Vourc'h, N., Leblond, V., Olayat, S., Gauthier, F., and Courty, Y. (2001). Characterization of PSA-RP2, a protein related to prostate-specific antigen and encoded by alternative hKLK3 transcripts. Eur. J. Biochem. 268, 4408-4413.
9. Heuze-Vourc'h, N., Leblond, V., and Courty, Y. (2003). Complex alternative splicing of the hKLK3 gene coding for the tumor marker PSA (prostate-specific-antigen). Eur. J. Biochem. 270, 706-714.
10. Khan, M.A., Sokoll, L.J., Chan, D.W., Mangold, L.A., Mohr, P., Mikolajczyk, S.D., Linton, H.J., Evans, C.L., Rittenhouse, H.G., and Partin, A.W. (2004). Clinical utility of proPSA and 'benign' PSA when percent free PSA is less than 15%. Urology 64, 1160-1164.
11. Kurlender, L., Borgono, C., Michael, I.P., Obiezu, C., Elliott, M.B., Yousef, G.M., and Diamandis, E.P. (2005). A survey of alternative transcripts of human tissue kallikrein genes. Biochim. Biophys. Acta 1755, 1-14.
12. Linton, H.J., Marks, L.S., Millar, L.S., Knott, C.L., Rittenhouse, H.G., and Mikolajczyk, S.D. (2003). Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin. Chem. 49, 253-259.
13. Lundwall, A. and Brattsand, M. (2008). Kallikrein-related peptidases. Cell. Mol. Life Sci. 65, 2019-2038.
14. Mikolajczyk, S.D., Catalona, W.J., Evans, C.L., Linton, H.J., Millar, L.S., Marker, K.M., Katir, D., Amirkhan, A., and Rittenhouse, H.G. (2004). Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin. Chem. 50, 1017-1025.
15. Riegman, P.H., Klaassen, P., van der Korput, J.A., Romijn, J.C., and Trapman, J. (1988). Molecular cloning and characterization of novel prostate antigen cDNAs. Biochem. Biophys. Res. Commun. 155, 181-188.
16. Sardana, G., Dowell, B., and Diamandis, E.P. (2008). Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin. Chem. 54, 1951-1960.
17. Stenman, U.H., Leinonen, J., Zhang, W.M., and Finne, P. (1999). Prostate-specific antigen. Semin. Cancer Biol. 9, 83-93.
18. Stephan, C., Rittenhouse, H., Cammann, H., Lein, M., Schrader, M., Deger, S., Miller, K., and Jung, K. (2009). New markers and multivariate models for prostate cancer detection. Anticancer Res. 29, 2589-2600.
19. Steuber, T., O'Brien, M.F., and Lilja, H. (2008). Serum markers for prostate cancer: a rational approach to the literature. Eur. Urol. 54, 31-40.
20. Sun, X.Y., Donald, S.P., and Phang, J.M. (2001). Testosterone and prostate-specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22, 1775-1780.
21. Tan, O.L., Whitbread, A.K., Clements, J.A., and Dong, Y. (2006). Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? Biol. Chem. 387, 697-705.
22. Veveris-Lowe, T.L., Lawrence, M.G., Collard, R.L., Bui, L., Herington, A.C., Nicol, D.L., and Clements, J.A. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr. Relat. Cancer 12, 631-643.